. . . . . . . . . . . . . . . . . . . . . . "\"DrugSyn.org\":http://www.drugsyn.org/Propranolol.htm"@en . . . . . . . . . . . "\u03B2-Propranolol"@en . "4 hours"@en . . . . . "approved"@en . . . . . . . "Propranolol is almost completely absorbed from the GI tract; however, plasma concentrations attained are quite variable among individuals."@en . . . . . . . . . "Propranolol is extensively metabolized with most metabolites appearing in the urine."@en . . . . . . . . . . . . . . "Humans and other mammals"@en . . . . . . . "Propranolol"@en . . . . . " "@en . . . . . . . . . . . . . . . "1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol"@en . . . . . . . . . . . . . . "A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem]"@en . . "Propranolol"@en . . . . "Avoid alcohol."@en . . . . . . "Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD₅₀=565 mg/kg (orally in mice)."@en . "Propranololo"@en . . "Propranolol competes with sympathomimetic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart, inhibiting sympathetic stimulation. This results in a reduction in resting heart rate, cardiac output, systolic and diastolic blood pressure, and reflex orthostatic hypotension."@en . . . . . . . . . "investigational"@en . . . . . . . . . . . . . . . . . . . . . . . . "More than 90%"@en . . . . " "@en . . . . . . "Take with food."@en . . . "Propanolol"@en . . . . . . . . . . . . . . . . . "525-66-6"@en . . . . . . . . . . "beta-Propranolol"@en . . . . . . . . . . . . . . . . . . . . . . . "* 4 L"@en . "Propanalol"@en . "Propranololum"@en . . "1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol"@en . . "Avoid natural licorice."@en . . . . . . . . . . "For the prophylaxis of migraine."@en . . . . . . . . . . . . . . . . "# Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK: Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res. 2007 Jun 21;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17588604 # Ohnishi ST, Sadanaga KK, Katsuoka M, Weidanz WP: Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes. Mol Cell Biochem. 1989 Nov 23-Dec 19;91(1-2):159-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/2695829 # Singh N, Puri SK: Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis. Acta Trop. 2000 Nov 2;77(2):185-93. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11080509 # Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K: Erythrocyte G protein as a novel target for malarial chemotherapy. PLoS Med. 2006 Dec;3(12):e528. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17194200"@en . .